nivolumab,ipilimumab,cabozantinib
bms
['lung', 'ipi/', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipi +', 'cabo ', 'nivo', 'cosmic-313']
triplet therapy in 1l rcc? provides an update on #cosmic313 nivo/ipi +/- cabo #gu23: pfs hr 0.74 when added cabo to ipi/nivo in all-comers pfs hr 0.68 in interm risk, no diff in exposure to explain not a regimen for use outside trial at this time, os pending 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast